UPCOMING CONFERENCES - ASCO 2022 (3-7 June) EH... - CLL Support
UPCOMING CONFERENCES - ASCO 2022 (3-7 June) EHA 2022 (9-12, 15-17 June)
You need to be a member of this community to see this post.
Read more about...
- Clinical trials
- Chemotherapy
- Ibrutinib
- Rituximab
- Vaccination
- Venetoclax
- Tyrosine
- Bendamustine
- Chlorambucil
- Obinutuzumab
- Chronic leukaemia
- Acalabrutinib
- Coronavirus
19 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'
In just a short time, in many places, BTK inhibitors (BTKi) have largely replaced...
Early results of the Pirtobrutinib, Obinituzumab, Venetoclax trial I'm on have just been published
Dr. Jain of M.D. Anderson has published an oral abstract in advance of the European Hematological...
EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor
https://cllsociety.org/2022/08/eha-2022-outcomes-following-treatment-with-a-covalent-btk-and-bcl2-in
News about V+O and Acalabrutinib from EHA
Hi,
The future of CLL therapy we believe will include fixed duration treatments of non-chemo drugs....
Zanubrutinib vs. Ibrutinib Patient Power Video by Dr. Jennifer Brown MD PHD
In this Patient Power video - Dr. Brown is very clear about the advantages of Zanubrutinib over...
Related Posts
YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success- Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia ( CLL ) - Pseudo Richters
- End of suspense! Here is Dr. Koffman's ASCO 2020 "Top Pick" #1!
- Dr. John Allan - Chronic Lymphocytic Leukemia (CLL) Patients @Undetectable Measurable Residual Disease (MRD) after Ibrutinib Plus Venetoclax
- CLL SOCIETY'S ASH POSTER on our Free second opinion program plus two important papers from ASCO
